Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 160807-49-8 Chemical Structure| 160807-49-8

Structure of Indirubin-3'-monoxime
CAS No.: 160807-49-8

Chemical Structure| 160807-49-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Indirubin-3'-monoxime is a powerful inhibitor of GSK-3β with IC50 of 22nM, also inhibits CDK1/5 (IC50 = 180/100 nM).

Synonyms: Indirubin-3'-oxime

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Indirubin-3'-monoxime

CAS No. :160807-49-8
Formula : C16H11N3O2
M.W : 277.28
SMILES Code : O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=N/O
Synonyms :
Indirubin-3'-oxime
MDL No. :MFCD02683594
InChI Key :FQCPPVRJPILDIK-UHFFFAOYSA-N
Pubchem ID :3707

Safety of Indirubin-3'-monoxime

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H228
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Related Pathways of Indirubin-3'-monoxime

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary MM patient samples 5 µM and 10 µM 72 hours I3MO significantly suppressed the growth of MM cells and induced apoptosis EBioMedicine. 2022 Apr;78:103950
KRIT1-depleted HUVECs 10 μM 48 hours Reduced pERK5 levels and KLF2 mRNA expression, restoring cell morphology EMBO Mol Med. 2018 Oct;10(10):e9155
human umbilical cord venous endothelial cells (HUVECs) 10 μM 48 hours Suppressed stress fiber formation and cell elongation in CCM2 shRNA-treated HUVECs, restoring cell morphology EMBO Mol Med. 2018 Oct;10(10):e9155
RCS cells 1 μM 3 days To evaluate the effect of I3O on chondrocyte differentiation, results showed that I3O enhanced the formation of cartilage nodules and synthesis of matrix proteoglycans. Exp Mol Med. 2019 Sep 12;51(9):1-10
ATDC5 cells 1 μM 48 hours To evaluate the effect of I3O on chondrocyte proliferation, results showed that I3O significantly promoted the growth of ATDC5 cells. Exp Mol Med. 2019 Sep 12;51(9):1-10
SW480 cells 20-25 μM To evaluate the effect of I3M on SW480 cell apoptosis, results showed 25 μM I3M induced approximately 40% apoptosis. Antioxidants (Basel). 2019 Sep 22;8(10):423
HT29 cells 20-25 μM To evaluate the effect of I3M on HT29 cell apoptosis, results showed 25 μM I3M induced approximately 40% apoptosis. Antioxidants (Basel). 2019 Sep 22;8(10):423
HCT116 p53-/- cells 5-20 μM 24 hours To evaluate the effect of I3M on HCT116 p53-/- cell viability, results showed I3M had minimal effect on cell viability. Antioxidants (Basel). 2019 Sep 22;8(10):423
HCT116 p53+/+ cells 5-20 μM 24 hours To evaluate the effect of I3M on HCT116 p53+/+ cell viability, results showed I3M decreased cell viability in a dose-dependent manner. Antioxidants (Basel). 2019 Sep 22;8(10):423
SH-SY5Y cells 0.2 µM, 0.5 µM, 1.0 µM 2 days IMX improved the morphology and increased the survival rate of SH-SY5Y cells exposed to amyloid-beta 25–35 (Aβ25–35), and suppressed apoptosis by reducing tau phosphorylation at Ser199 and Thr205. Neural Regen Res. 2016 Jun;11(6):988-93
ANBL6-BR 5.76 ± 0.34 µM 96 hours I3MO significantly suppressed the growth of MM cells and induced apoptosis EBioMedicine. 2022 Apr;78:103950
ANBL6 9.47 ± 1.37 µM 96 hours I3MO significantly suppressed the growth of MM cells and induced apoptosis EBioMedicine. 2022 Apr;78:103950
RPMI8226 8.88 ± 0.79 µM 96 hours I3MO significantly suppressed the growth of MM cells and induced apoptosis EBioMedicine. 2022 Apr;78:103950
U266 9.92 ± 1.21 µM 96 hours I3MO significantly suppressed the growth of MM cells and induced apoptosis EBioMedicine. 2022 Apr;78:103950
ARP1 5.56 ± 0.71 µM 96 hours I3MO significantly suppressed the growth of MM cells and induced apoptosis EBioMedicine. 2022 Apr;78:103950
KMS11-BR 5 μM and 10 μM 24 hours To evaluate the inhibitory effect of 8b on MM cell proliferation, results showed that 8b significantly suppressed MM cell proliferation and induced apoptosis. Biomark Res. 2025 Apr 7;13(1):57
KMS11 5 μM and 10 μM 24 hours To evaluate the inhibitory effect of 8b on MM cell proliferation, results showed that 8b significantly suppressed MM cell proliferation and induced apoptosis. Biomark Res. 2025 Apr 7;13(1):57
U266 5 μM and 10 μM 24 hours To evaluate the inhibitory effect of 8b on MM cell proliferation, results showed that 8b significantly suppressed MM cell proliferation and induced apoptosis. Biomark Res. 2025 Apr 7;13(1):57
RPMI8226 5 μM and 10 μM 24 hours To evaluate the inhibitory effect of 8b on MM cell proliferation, results showed that 8b significantly suppressed MM cell proliferation and induced apoptosis. Biomark Res. 2025 Apr 7;13(1):57
ARP1 5 μM and 10 μM 24 hours To evaluate the inhibitory effect of 8b on MM cell proliferation, results showed that 8b significantly suppressed MM cell proliferation and induced apoptosis. Biomark Res. 2025 Apr 7;13(1):57
SH-SY5Y cells 0.1–1000 μM 72 hours To evaluate cytotoxicity, the results showed that indirubin-3'-monoxime 5aa reduced cell survival rate below 50% at 10 mM concentration. RSC Adv. 2022 Sep 2;12(38):25068-25080
S. aureus ATCC25923 0.4–25.6 mg/mL 16–24 hours To evaluate antibacterial activity, the results showed that the synthesized indirubin-3'-monoximes had good antibacterial effects against S. aureus ATCC25923. RSC Adv. 2022 Sep 2;12(38):25068-25080

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Drosophila melanogaster Heat-induced male infertility model Dietary supplementation 1 µM, 5 µM, 10 µM Continuous exposure to 27.5°C To evaluate the protective effect of I3O on heat-induced male infertility, results showed that I3O partially restored male fertility. J Enzyme Inhib Med Chem. 2025 Dec;40(1):2447719
NOD/SCID mice Multiple myeloma xenograft model Intraperitoneal injection 1.25 mg/kg and 6 mg/kg Every other day for two weeks I3MO significantly reduced tumor burden, and combination therapy with bortezomib showed enhanced efficacy EBioMedicine. 2022 Apr;78:103950
Mouse ICCM2 and iCCM3 mouse models Oral 10 mg/kg Daily for 6 days (P2 to P7) Alleviated cerebellar lesion burden, reducing the number of small lesions EMBO Mol Med. 2018 Oct;10(10):e9155
Mice C57BL/6 mice Intraperitoneal injection 0.05 or 0.5 mg/kg Daily for 2 or 10 weeks To evaluate the effect of I3O on in vivo bone growth, results showed that I3O significantly increased tibial length, promoted growth plate activation, and had no significant adverse effects on bone thickness and articular cartilage. Exp Mol Med. 2019 Sep 12;51(9):1-10
APP transgenic mice Alzheimer's disease model Systemic administration 20 mg/kg 3 times per week for 2 months IMX attenuated spatial memory deficits and decreased PS1 mutations, improving AD-like phenotypes. Neural Regen Res. 2016 Jun;11(6):988-93

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.61mL

0.72mL

0.36mL

18.03mL

3.61mL

1.80mL

36.06mL

7.21mL

3.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories